Stock Watch: Will MacroGenics' SOPHIA Make Heads Turn Again?

MacroGenics Inc. (MGNX) has reported updated results from its phase III study of Margetuximab in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies.

from RTT - Biotech http://bit.ly/2EcM28K
via IFTTT